Dipna Pharmachem logo

Dipna Pharmachem financials and balance sheet

BSE: 543594Pharmaceuticals & BiotechnologySmall Cap

Last close ₹3.89down ₹0.04 (1.02%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹3.93.

52-week range of traded prices to 23 Oct 2026
₹3.89Low, 8 Oct 2026₹20.50High, 30 Oct 2025
Market cap
₹10 Cr3,953rd largest listed
P/E
No recent results
P/B
No recent results
Dividend yield
Nonein the last 12 months
Volume, BSE
18,000

4 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Dipna Pharmachem annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
Peak revenue ₹164 Cr, year to Mar 2024

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue129
  2. Materials and goods−107
  3. Employee costs−0.4
  4. Other expenses−16
  5. Operating profit5.0
  6. Depreciation0.0
  7. Other income0.0
  8. One-off items0.0
  9. Finance costs−1.5
  10. Profit before tax3.5
  11. Tax−0.9
  12. Net profit2.6

What the company owns

  • Plant, investments and other assets₹114 Cr
  • Receivables₹48 Cr
  • Inventory₹42 Cr
  • Cash and bank₹1 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹110 Cr
  • Net worth₹62 Cr
  • Other liabilities₹20 Cr
  • Borrowings₹13 Cr

Dipna Pharmachem business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Standalone, ₹ crore, as the company reports them. A segment at a loss has no share of profit.Dipna Pharmachem segment results by quarter

Revenue by segment

₹129 CrTotal
  • Steel Segment₹70.9 Cr54.9% of total
  • Chemicals Segment₹58.2 Cr45.1% of total

Profit by segment

  • Steel Segment₹8.67 Cr100.0% of total

Segment results by year

Standalone, ₹ crore, years to March.

  • Steel Segment

    Revenue, ₹ crore
    Profit, ₹ crore
  • Chemicals Segment

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2023Mar 2024Mar 2025Mar 2026
Revenue of all businesses–––129
Company revenue, as in its results100164125129
Revenue–––71
Profit–––9
Margin–––12.2%
Assets–––7
Liabilities–––21
Capital employed–––−14
Revenue–––58
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Standalone, ₹ crore, years to March.Dipna Pharmachem quarterly results

₹ croreMar 2023Filed 11 JulMar 2024Filed 9 AugMar 2025Filed 7 JulMar 2026Filed 2 Jul
Revenue from operations100164125129
98161121124
Materials and goods bought95158114107
Employee costs0000
Other expenses23716
Operating profit before depreciation2335
Operating margin2.3%2.1%2.7%3.9%
Materials, % of revenue95.6%96.1%91.0%83.3%
Employee costs, % of revenue0.4%0.3%0.3%0.3%
Other expenses, % of revenue1.7%1.6%5.9%12.5%
Depreciation and amortisation0000
Operating profit after depreciation2335
Other income0000
Finance costs1221
One-off items–––0
Profit before tax1114
0001
Net profit1113
Net margin0.9%0.7%0.8%2.0%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2023Filed 11 JulMar 2024Filed 9 AugMar 2025Filed 7 JulMar 2026Filed 2 Jul
24383862
Share capital12242426
Reserves12131436
16191713
398385133
Liabilities due after a year1413910
Total assets78133132206
00052
78133132154
Net debt1061712
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2023Filed 11 JulMar 2024Filed 9 AugMar 2025Filed 7 JulMar 2026Filed 2 Jul
−21.0−5.4−9.2−18.3
−20.5−5.1−8.7−17.4
−22.9−8.5−12.2−22.4
Receivables−1.6−2.4−15.3−0.7
Inventories−12.6−18.49.9−14.9
Payables13.038.31.239.0
Other working capital−21.7−25.9−8.0−45.9
Tax paid0.00.00.0−0.9
Interest paid0.0−0.3−0.40.0
Capital spending0.00.00.00.0
Free cash flow−21.0−5.4−9.2−18.4
Cash from investing0.00.00.00.0
26.513.6−4.218.8
Dividends paid0.00.00.00.0
Shares bought back–––0.0
Shares issued21.712.10.0–
Net change in cash5.58.2−13.50.4
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. Shares issued is left blank for the year to Mar 2026: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2023Filed 11 JulMar 2024Filed 9 AugMar 2025Filed 7 JulMar 2026Filed 2 Jul
Earnings per share₹0.76₹0.90₹0.41₹1.00
Diluted earnings per share₹0.76₹0.90₹0.41₹1.00
Book value per share₹20.35₹15.60₹16.01₹23.70
Shareholder yield−144.5%−107.1%0.0%–
Market cap at the year end (₹ crore)15.011.334.421.1
Shareholder yield is left blank for the year to Mar 2026: the money stated as raised on shares and other equity instruments is more than three times what the shares issued in the period were worth at its end, so not all of it bought shares and the figure is not given.

Ratios

Standalone, years to March.Dipna Pharmachem PE ratio and valuation

RatioMar 2023Filed 11 JulMar 2024Filed 9 AugMar 2025Filed 7 JulMar 2026Filed 2 Jul
Revenue growth–64.5%−24.0%3.3%
Operating profit growth–46.3%0.2%45.5%
Net profit growth–19.0%−10.2%170.2%
Earnings per share growth–18.4%−54.4%143.9%
3.7%3.5%2.6%5.2%
–−0.2 pts−0.9 pts2.7 pts
From the net margin–−1.0 pts0.6 pts4.1 pts
From asset turnover–0.6 pts−1.6 pts−1.3 pts
From borrowing–0.2 pts0.1 pts−0.2 pts
Return on capital employed5.8%6.0%6.1%6.6%
Cash conversion−2,300.5%−499.1%−943.9%−696.2%
Interest cover2.41.71.73.4
Debt to equity0.650.520.450.21
Receivable days10469135136
Inventory days728688144
Payable days––243375
Cash conversion cycle, days––−20−95
Working capital days1269616164
Asset turnover1.291.560.940.76
Assets per rupee of net worth3.183.403.493.35
Sales per rupee of plant2,523.414,417.662,721.511,785.38
Capital spending to depreciation0.000.861.762.85
Plant being built, % of plant in use–––0.0%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
1.6%
Cash from operations against operating profit
−366.7%
Measure5 years3 years
Revenue growth, yearly rate–8.9%
Profit growth, yearly rate–42.4%
Return on equity, average3.8%3.8%
Return on capital employed, average6.1%6.2%
Operating margin, average2.8%2.9%
Net margin, average1.1%1.2%
Asset turnover, average1.141.09
Cash conversion cycle, days, average–−58
Interest cover, average2.32.3
Debt to equity, average0.460.39

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore3 yearsLatest year
Cash from operations−32.9−18.3
Cash from investing−0.10.0
Cash from financing28.218.8
Capital spending0.10.0
Dividends paid0.00.0
Shares bought back–0.0
Borrowings raised–0.0
Borrowings repaid0.90.9

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81–––1.16
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––12.42
Receivables growth less revenue growthOur threshold 0 percentage points–−56.0373.570.40
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–31.971.3759.77
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–16.016.023.39
Assets under construction, years of additionsOur threshold 2 years of additions–––0.00
Effective tax ratePublished threshold 17.16 per cent33.9823.5431.4025.75
Tax charged less tax paid, % of profitOur threshold 10 percentage points33.9823.5431.40−0.10
A threshold marked as ours has no published figure; it is the line we read the check against.